title: Apolipoprotein A-IV is involved in detection of lipid in the rat intestine.
abstract: Long chain triglyceride (>C12) in the intestinal lumen potently inhibits gastric emptying and acid secretion via the vagal afferent pathway. While the mechanism of inhibition involves the formation of chylomicrons, the essential role of the apolipoprotein apo A-IV is unclear. Using apo A-IV(-/-) mice, we tested the hypothesis that inhibition of gastric emptying and gastric acid secretion in response to dietary lipid is dependent upon apo A-IV. As measured by nuclear scintigraphy in awake mice, gastric emptying of an ingested whole-egg meal was significantly faster in apo A-IV(-/-) knockout versus A-IV(+/+) controls (34 +/- 1 versus 54 +/- 3 min, P < 0.0001). In anaesthetized A-IV(+/+) mice, meal-stimulated gastric acid secretion was 59% inhibited by intestinal lipid infusion; this was abolished in apo A-IV(-/-) mice. Oral gavage of lipid in awake mice activated neurones throughout the nucleus of the solitary tract (NTS) in A-IV(+/+) mice, measured by immunohistochemical localization of Fos protein expression. However, in the mid region of the NTS (bregma -7.32 to -7.76 mm), Fos expression in response to intestinal lipid was significantly decreased by 50% in apo A-IV(-/-) mice compared to A-IV(+/+) controls. We conclude that activation of the vagal afferent pathway and inhibition of gastric function in response to dietary lipid is partly dependent upon apo A-IV.
authors.affiliation: 1321 Haring Hall, Vet Med: APC, UC Davis School of Veterinary Medicine, Davis, CA 95616, USA.
authors.forename: K L
authors.initials: KL
authors.lastname: Whited
authors.forename: D
authors.initials: D
authors.lastname: Lu
authors.forename: P
authors.initials: P
authors.lastname: Tso
authors.forename: K C
authors.initials: KC
authors.lastname: Kent Lloyd
authors.forename: H E
authors.initials: HE
authors.lastname: Raybould
mesh_terms: D000818:Animals; D001054:Apolipoproteins A / Q000235:genetics / Q000502:physiology*; D002766:Cholecystokinin / Q000008:administration & dosage / Q000494:pharmacology; D020109:Devazepide / Q000494:pharmacology; D005744:Gastric Acid / Q000378:metabolism; D005746:Gastric Emptying / Q000187:drug effects; D006727:Hormone Antagonists / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects* / Q000294:innervation; D007441:Intubation, Gastrointestinal; D008055:Lipids / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D017552:Solitary Nucleus / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014630:Vagus Nerve / Q000187:drug effects
chemical_list: D001054:Apolipoproteins A; D006727:Hormone Antagonists; D008055:Lipids; D016760:Proto-Oncogene Proteins c-fos; D014280:Triglycerides; C022205:apolipoprotein A-IV; D002766:Cholecystokinin; D020109:Devazepide